Cleared Is Not Approved: The 510(k) Pathway and Substantial Equivalence

A 510(k) clearance means the FDA agreed a device is substantially equivalent to one already on the market, not that a study showed it helps patients. It compares intended use and technological characteristics against a predicate device rather than requiring independent proof of safety and effectiveness. Reading the evidence means asking what the predicate was, and what data, if any, were generated for the new device itself.

Clearance and approval are different words for a reason

The words matter. Under the Food, Drug, and Cosmetic Act, most moderate-risk devices reach the market through premarket notification, known by its statute section as 510(k). A manufacturer notifies the FDA that its device is substantially equivalent to a product already legally sold, called a predicate. If the agency agrees, the device is cleared. High-risk devices, by contrast, usually go through premarket approval, which does require valid scientific evidence that the device is safe and effective for its intended use.

So when a company says its device is FDA cleared, that is a precise regulatory claim. It means the agency accepted an equivalence argument. It does not, on its own, mean a study showed the device works.

What substantial equivalence actually asks

The FDA guidance lays the decision out as a chain of questions. Does the new device have the same intended use as the predicate? If the technological characteristics differ, do those differences raise different questions of safety and effectiveness? And do the data show the new device is as safe and effective as the predicate?

Substantial equivalence does not mean identical. A newer device can use different materials or a different design and still clear, as long as the differences do not open new safety questions and performance data support equivalence. The comparison is always relative to the predicate, not to an absolute standard of patient benefit.

The predicate chain and where it can drift

Every predicate was itself once cleared against an earlier predicate. That chain can stretch back to devices that were on the market before the modern device amendments took effect. The Institute of Medicine, reviewing the process at the FDA's request, noted that this lineage means a current device may rest on a foundation laid long before today's evidence expectations.

This is where a careful reader slows down. A cleared device is only as well tested as the evidence somewhere in its chain. Sometimes that includes clinical data on the new device. Often it does not. The clearance letter and summary, which the FDA posts publicly, tell you which predicate was used and what testing was submitted.

When clearance does include real data

Clearance is not automatically evidence-free. For many devices the FDA requires bench testing, and for some it requires clinical performance data, especially when technological differences raise questions that only human data can settle. A diagnostic device, for instance, may need studies of sensitivity and specificity against a reference standard.

The point is not that a 510(k) is worthless. It is that the amount of evidence varies enormously from one clearance to the next, and the word cleared alone does not tell you where on that range a given device sits.

How to read a clearance claim

Start by separating the marketing word from the regulatory fact. Ask three plain questions. What predicate was this device cleared against, and how similar is it really? What testing was submitted for this specific device, bench or clinical? And is anyone claiming a patient benefit that would actually require a trial to support?

For the highest-risk devices, premarket approval and its scientific-evidence standard is the right expectation. For moderate-risk devices, substantial equivalence is the rule, and that is a reasonable regulatory design. Trouble starts only when a cleared device is marketed as if it had crossed the higher bar. Knowing the difference lets you read the claim for what it is.